NCT05385315Recruiting
Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease
Evaluation De La Performance Clinique D'un Nouveau Biomarqueur Sanguin Des Phases Précoces De La Maladie De Parkinson
Source: ClinicalTrials.gov · Last updated 11 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The investigators have recently discovered a metabolic biomarker which predicts Parkinson's disease (PD) at the early stages in patients and in animal models. The aim of BIOPARK is to investigate how the biomarker evolves in advanced PD stage, when diagnosis confirmation is higher, an in de novo PD patients who come from a different geographical area than those of the publication (since it is known that the metabolome is largely influenced by lifestyle). They will also evaluate if the biomarker is able to distinguish patients with a parkinsonian syndrome often confused with parkinson's disease, i.e. Multiple System Atrophy (MSA).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 17 May 2022
- Start date
- 13 Oct 2022
- Primary completion date
- 16 Oct 2025
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Parkinson disease
- NCT number
- NCT05385315
What you commit to
- Study type: Observational
- Planned participants: 70
- From 13 Oct 2022 to the primary completion date, 16 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other neurodegenerative diseases
Other
- Patients with deep brain stimulation
- patients protected by french law (pregnant or lactating women, prisoners, ...)
Who the study is looking for
- Patients with de novo Parkinson's disease, without dopaminergic treatment
- Patients with advanced Parkinson's disease (\> 5years) with dopaminergic treatment
- Patients with multiple system atrophy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.